GMB 475 is a BCR-ABL1 kinase PROTAC™ Degrader. Induces degradation of BCR-ABL1 and cABL1, inhibits downstream STAT5 signaling and suppresses cell proliferation in chronic myeloid leukemia cells lines. PROTAC™ is a registered trademark of Arvinas Operations, Inc., and is used under license.
- Nom chimique ou matériau
- (2 S,4 R)-1-(-3,3-Dimethyl-2-(2-(2-(4-(6-((4-(trifluoromethoxy)phenyl)amino)pyrimidin-4-yl)phenoxy)ethoxy)acetamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
- CAS
- 2490599-18-1
- Quantité
- 5 mg
- Cible
- Active Degraders
- Formule moléculaire
- C43H46F3N7O7S
- Pureté
- 0.98
